Effect of Dornase Alfa on the Lung Clearance Index in Children with Cystic Fibrosis: A Lesson from a Case Series.
DNase
children
cystic fibrosis
dornase alfa
lung clearance index
lung function
Journal
Children (Basel, Switzerland)
ISSN: 2227-9067
Titre abrégé: Children (Basel)
Pays: Switzerland
ID NLM: 101648936
Informations de publication
Date de publication:
26 Oct 2022
26 Oct 2022
Historique:
received:
23
09
2022
revised:
15
10
2022
accepted:
24
10
2022
entrez:
11
11
2022
pubmed:
12
11
2022
medline:
12
11
2022
Statut:
epublish
Résumé
Dornase alfa (DNase) is the only mucus-degrading agent that has proven efficacy in cystic fibrosis (CF). Few studies have evaluated the effects of DNase on the lung clearance index (LCI). We report the experience of two CF centers in which LCI monitoring was used to evaluate the efficacy of DNase therapy. This is a prospective and observational study, evaluating the effects of DNase therapy on LCI values in three CF children followed at CF centers in Florence and Catania, Italy. In both centers, LCI was performed routinely, every 3-6 months, based on the clinical picture and severity of the lung disease. In this study, we evaluated the LCI before and after long-term DNase therapy. DNase improved LCI values in the absence of respiratory exacerbations: in case n. 1 LCI decreased by 39% in 16 months (from 11.1 to 6.8); in case n. 2 by 20% in 12 months (from 9.3 to 7.4); in case n. 3 by 24% in 16 months (from 9.3 to 7.0). This case series confirms the efficacy of DNase therapy in CF children, as demonstrated by the LCI reduction in treated patients. Furthermore, our results suggest that LCI is a sensitive marker of disease and can be used for the evaluation of response to treatment.
Sections du résumé
BACKGROUND
BACKGROUND
Dornase alfa (DNase) is the only mucus-degrading agent that has proven efficacy in cystic fibrosis (CF). Few studies have evaluated the effects of DNase on the lung clearance index (LCI). We report the experience of two CF centers in which LCI monitoring was used to evaluate the efficacy of DNase therapy.
METHODS
METHODS
This is a prospective and observational study, evaluating the effects of DNase therapy on LCI values in three CF children followed at CF centers in Florence and Catania, Italy. In both centers, LCI was performed routinely, every 3-6 months, based on the clinical picture and severity of the lung disease. In this study, we evaluated the LCI before and after long-term DNase therapy.
RESULTS
RESULTS
DNase improved LCI values in the absence of respiratory exacerbations: in case n. 1 LCI decreased by 39% in 16 months (from 11.1 to 6.8); in case n. 2 by 20% in 12 months (from 9.3 to 7.4); in case n. 3 by 24% in 16 months (from 9.3 to 7.0).
CONCLUSIONS
CONCLUSIONS
This case series confirms the efficacy of DNase therapy in CF children, as demonstrated by the LCI reduction in treated patients. Furthermore, our results suggest that LCI is a sensitive marker of disease and can be used for the evaluation of response to treatment.
Identifiants
pubmed: 36360353
pii: children9111625
doi: 10.3390/children9111625
pmc: PMC9688561
pii:
doi:
Types de publication
Journal Article
Langues
eng
Références
Eur Respir J. 2013 Mar;41(3):507-22
pubmed: 23397305
J Pediatr Gastroenterol Nutr. 2012 Feb;54(2):277-80
pubmed: 22266489
Lancet Respir Med. 2017 Jul;5(7):557-567
pubmed: 28606620
Am J Respir Crit Care Med. 2012 Apr 15;185(8):862-73
pubmed: 22323305
Eur Respir J. 2017 Oct 5;50(4):
pubmed: 28982773
J Cyst Fibros. 2019 Sep;18(5):721-727
pubmed: 30827846
Lancet. 2021 Jun 5;397(10290):2195-2211
pubmed: 34090606
Eur Respir J. 2020 Apr 3;55(4):
pubmed: 31862765
Ital J Pediatr. 2022 Aug 4;48(1):141
pubmed: 35927765
Eur Respir J. 2012 Dec;40(6):1324-43
pubmed: 22743675
Gut. 1996 Oct;39(4):580-6
pubmed: 8944569
Thorax. 2008 Feb;63(2):135-40
pubmed: 17675315
Paediatr Respir Rev. 2011 Dec;12(4):264-70
pubmed: 22018042
Pediatr Pulmonol. 2020 Dec;55(12):3450-3456
pubmed: 32926567
Swiss Med Wkly. 2017 Sep 05;147:w14483
pubmed: 28871575
Cochrane Database Syst Rev. 2018 Sep 06;9:CD001127
pubmed: 30187450
N Engl J Med. 1994 Sep 8;331(10):637-42
pubmed: 7503821
Eur Clin Respir J. 2014 Oct 17;1:
pubmed: 26557240
J Cyst Fibros. 2003 Mar;2(1):29-34
pubmed: 15463843
Ann Am Thorac Soc. 2020 Sep;17(9):1085-1093
pubmed: 32603187
Paediatr Respir Rev. 2017 Jan;21:65-67
pubmed: 27769785
J Cyst Fibros. 2020 Nov;19(6):931-933
pubmed: 32513528
Lancet Respir Med. 2019 Sep;7(9):802-809
pubmed: 31178421
Am J Respir Crit Care Med. 2016 Jan 1;193(1):60-7
pubmed: 26359952
Eur Respir J. 2011 Apr;37(4):806-12
pubmed: 20693248
J Cyst Fibros. 2021 Nov;20(6):949-956
pubmed: 33619014
Thorax. 2004 Dec;59(12):1068-73
pubmed: 15563707
Am J Respir Crit Care Med. 2009 Nov 1;180(9):802-8
pubmed: 19729669
Respir Med. 2020 Apr;164:105906
pubmed: 32217291
Am J Respir Crit Care Med. 2013 Oct 15;188(8):e13-64
pubmed: 24127811
J Cyst Fibros. 2016 Jul;15(4):416-23
pubmed: 27316663
Int J Neonatal Screen. 2022 Aug 03;8(3):
pubmed: 35997436
Mol Genet Genomic Med. 2021 Apr;9(4):e1656
pubmed: 33713579
Lancet. 2001 Oct 20;358(9290):1316-21
pubmed: 11684212
Respiration. 2009;78(3):339-55
pubmed: 19521061
Am J Respir Crit Care Med. 2018 Aug 15;198(4):526-528
pubmed: 29614238
Lancet Respir Med. 2013 Oct;1(8):630-638
pubmed: 24461666
Respir Med. 2021 Nov-Dec;189:106646
pubmed: 34673344
J Cyst Fibros. 2018 Mar;17(2):236-241
pubmed: 28822728